UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): October 24, 2008

VioQuest Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)

Delaware
000-16686
58-1486040
(State or other jurisdiction of
(Commission File Number)
(IRS Employer
incorporation)
  
Identification No.)

180 Mt. Airy Road, Suite 102
Basking Ridge, NJ 07920
(Address of principal executive offices)

(908) 766-4400
(Registrant's telephone number, including area code)

N/A
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Item 5.02
Departure of Directors or Certain Officers.

On October 24, 2008, VioQuest Pharmaceuticals, Inc. (the “Company”) provided a strategic alternatives review and operations update and released the press release filed herewith as Exhibit 99.1 to this Current Report on Form 8-K and the press release is incorporated herein by reference.
 
Item 8.01
Other Events.

On October 24, 2008, the Company provided a strategic alternatives review and operations update and released the press release filed herewith as Exhibit 99.1 to this Current Report on Form 8-K and the press release is incorporated herein by reference.
 
Item 9.01
Financial Statements and Exhibits.

(d)
Exhibits
 
Exhibit No.
  
Description
     
99.1
 
Press release of the Company dated October 24, 2008.
 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
   
 VioQuest Pharmaceuticals, Inc.
     
By:
/s/ Christopher P. Schnittker
   
Christopher P. Schnittker
   
Vice President &
   
Chief Financial Officer